Is interstitial pneumonia with fibrosis in both lungs treatable—Department of Respiratory Medicine

Interstitial pneumonia with pulmonary fibrosis is a complex and often progressive condition that affects the lung’s interstitium—the network of tissue surrounding the air sacs (alveoli). While some forms of interstitial lung disease (ILD) may respond to treatment—particularly when an identifiable, reversible cause is present (e.g., drug-induced ILD, hypersensitivity pneumonitis, or connective tissue disease–associated ILD)—idiopathic pulmonary fibrosis (IPF), the most common and prototypical form of progressive fibrosing ILD, is not curable. Current therapies aim to slow disease progression, preserve lung function, reduce acute exacerbations, and improve quality of life—not to reverse established fibrosis.

Two antifibrotic medications—nintedanib and pirfenidone—are FDA- and EMA-approved for IPF and certain other progressive fibrosing ILDs. Clinical trials demonstrate they significantly reduce the rate of forced vital capacity (FVC) decline by approximately 50% over one year compared with placebo. However, neither drug halts disease entirely nor restores normal lung architecture. Supportive care—including supplemental oxygen for hypoxemia, pulmonary rehabilitation, vaccination against influenza and pneumococcus, and management of comorbidities—is essential. In select patients with advanced disease and appropriate clinical criteria, lung transplantation remains the only potentially life-extending intervention.

Prognosis varies widely depending on the underlying etiology, histopathologic pattern, rate of functional decline, and individual response to therapy. Multidisciplinary evaluation—including high-resolution CT imaging, pulmonary function testing, and sometimes surgical lung biopsy—is critical for accurate diagnosis and risk stratification. Early referral to a specialized ILD center improves diagnostic accuracy and access to clinical trials and emerging therapies.